The National Cancer Institute (NCI) awarded a $460,985 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University to develop a new therapeutic strategy to target liver metastasis in colon cancer. The research aims to determine the efficacy of dopamine D4 receptor (DRD4) agonists, alone or in combination with anti-cancer drugs, to prevent or lower the incidence of liver metastasis in preclinical animal models. The project will also elucidate the molecular mechanisms by which DRD4 regulates the VEGF-C/FLT4 axis, which may be a key driver of liver metastasis in colon cancer patients. The project will be conducted at The Ohio State University from March 1, 2025 to February 28, 2030, with the goal of identifying novel therapeutic approaches to improve outcomes for colon cancer patients at risk of developing deadly liver metastases.
Generated 3/18/25, 4:02 AM